People: Atara Biotherapeutics Inc (ATRA.OQ)
18 Apr 2019
Dr. Christopher M. Haqq, M.D. Ph.D. serves as Executive Vice President - Research and Development, Chief Scientific Officer of the Company. From September 2011 to August 2012, Dr. Haqq served as the Chief Executive Officer of Genomic Systems, a biotechnology company. From 2007 to September 2011, Dr. Haqq served as Vice President for Clinical Research and Development at Cougar Biotechnology, Inc., a cancer-focused biotechnology company that was acquired by Johnson & Johnson in 2009, and Johnson & Johnson’s Janssen Pharmaceutical Companies division. Prior to that time, Dr. Haqq served in drug development roles at Amgen Inc., a biotechnology company, and practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. Dr. Haqq received a B.S. degree from Stanford University and an M.D. and Ph.D. from Harvard Medical School.
|Total Annual Compensation, USD||570,752|
|Restricted Stock Award, USD||2,723,500|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||3,768|
|Fiscal Year Total, USD||3,298,020|